A single-pill treatment to suppress HIV proved as effective as existing therapies of up to 11 tablets daily, the latest advance in a scientific “golden age” for treating the virus even as rich ...

A phase 3 clinical trial, led by Professor Chloe Orkin of Queen Mary University of London, has shown that a new, daily oral tablet that combines two current HIV treatment medications – bictegravir and ...

A new, daily oral tablet that combines two current HIV treatment medications, bictegravir and lenacapavir (BIC/LEN), may be able to effectively replace more complicated HIV treatment regimens used by ...

Feb 25 (Reuters) - Gilead Sciences on Wednesday said its experimental single-tablet HIV treatment was generally well ...

People who have lived with HIV long-term can need up to a dozen pills every day to suppress the virus. Results from a new ...

Merck said a treatment it is developing for HIV-1 met its primary endpoint in three Phase 3 trials. The biopharmaceutical company said Wednesday the results add to growing evidence for ...

– Investigational Long-Acting, Twice-Yearly Treatment Regimen of Lenacapavir and Broadly Neutralizing Antibodies (bNAbs) Meets Primary Endpoint in Phase 2 Study and Gains Breakthrough Therapy ...

As GSK’s HIV unit ViiV Healthcare grapples with a new rival in the injectable HIV prevention and treatment field, the company is reinforcing the staying power of its long-acting treatment Cabenuva | ...

Zimbabwe is one of the world's first countries to roll out lenacapavir, a long-acting HIV prevention drug that is ...

While medical breakthroughs have made ending HIV transmission a realistic goal, experts warn that stigma and misinformation ...

The Philadelphia HIV Resource Finder allows Philadelphians to search for treatment and prevention resources throughout the city.

TACLOBAN CITY – The island town of Biri in Northern Samar has opened an HIV Treatment Hub to strengthen healthcare service ...